Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Disodium Hydrogen Phosphate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Introduces Sodium Phosphates Injection, USP; FDA-Approved and "AP" Rated¹
Details : Sodium Phosphate is an approved small molecule, indicated as a source of phosphorous, for addition to large volume IV fluids, to prevent hypophosphatemia in patients with restricted or no oral intake.
Brand Name : Sodium Phosphate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 02, 2024
Lead Product(s) : Disodium Hydrogen Phosphate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Introduces Potassium Phosphates, USP; FDA-Approved and "AP" Rated¹
Details : Potassium Phosphates intravenous injection is a phosphorus replacement product indicated as a source of phosphorus, which is indicated for s to correct hypophosphatemia in adults and pediatric patients 12 years of age and older.
Brand Name : Potassium Phosphate-Geneic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 19, 2023
Lead Product(s) : Potassium Phosphate
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Levocarnitine is a carrier molecule in the transport of long-chain fatty acids across the inner mitochondrial membrane, which is indicated in the treatment of primary systemic carnitine deficiency.
Brand Name : Carnitor-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 10, 2023
Lead Product(s) : Levocarnitine
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®
Details : Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.
Brand Name : Injectafer
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 26, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Study Phase : Approved
Recipient : Daiichi Sankyo
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Injectafer (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with iron deficiency in adult patients with heart failure categorized.
Brand Name : Injectafer
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 05, 2023
Lead Product(s) : Ferric Carboxymaltose
Therapeutic Area : Hematology
Highest Development Status : Approved
Recipient : Daiichi Sankyo
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Paclitaxel protein-bound particles for injectable suspension is a microtubule inhibitor that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. It is indicated for metastatic breast cance...
Brand Name : Paclitaxel-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2023
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Launches Paclitaxel Protein-Bound Particles Injectable Suspension
Details : Paclitaxel protein-bound particles is a microtubule inhibitor indicated for metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer & metastatic pancreatic adenocarcinoma.
Brand Name : Paclitaxel Protein-Bound Particles
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 02, 2023
Lead Product(s) : Paclitaxel
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Introduces FDA-Approved Epinephrine Injection, USP
Details : Epinephrine is a nonselective alpha- and beta-adrenergic receptor agonist. Through its action on alpha-adrenergic receptors, it reduces vasodilation and increases vascular permeability that occurs during anaphylaxis.
Brand Name : Epinephrine-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 23, 2023
Lead Product(s) : Epinephrine
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Launches FDA-Approved Atropine Sulfate Injection, USP
Details : Atropine Sulfate Injection inhibits the muscarinic actions of acetylcholine, which is indicated for temporary blockade of severe or life-threatening muscarinic effects and to treat bradyasystolic cardiac arrest.
Brand Name : Atropine Sulfate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 09, 2022
Lead Product(s) : Atropine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Study Phase : Approved
Sponsor : Provepharm Life Solutions
Deal Size : Not Applicable
Deal Type : Not Applicable
American Regent Launches a New Vial Presentation
Details : ProvayBlue (methylene blue) is hypotonic and may be diluted before use in a solution of 50 mL 5% Dextrose Injection in order to avoid local pain, particularly in the pediatric population. Use the diluted solution immediately after preparation.
Brand Name : ProvayBlue
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 30, 2022
Lead Product(s) : Methylene Blue
Therapeutic Area : Hematology
Highest Development Status : Approved
Sponsor : Provepharm Life Solutions
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?